Furthermore, the treatment with radium-223 resulted in lower PSA values and reduced total tissue and tumor areas compared to the vehicle control, indicating that radium-223 constrains prostate cancer growth in bone. The gene discussed is KLK3; the disease is prostate carcinoma.